" class="no-js "lang="en-US"> Lipella Doses First Patient in Innovative Contrast Agent Study
Monday, June 05, 2023

Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent

Lipella Pharmaceuticals, a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announces it has dosed the first patient in its human clinical study of a novel bladder MRI contrast agent.

Lipella’s contrast agent is composed of two MRI contrast agents and is expected to be useful for the diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS) and potentially other bladder diseases characterized by bladder wall defects. Lipella believes the agent may also have utility in detecting bladder tumor progression to muscle-invasive bladder cancer.

The study is being funded by a $1.35 million Small Business Innovation Research (SBIR) Phase II grant awarded to Lipella by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2022. The two-year grant will support the clinical development of intravesical contrast-enhanced magnetic resonance imaging (ICE-MRI) technology, and is expected to accelerate clinical development of ICE-MRI, which could lead to important clinical results.

Dr. Michael Chancellor, Chief Medical Officer of Lipella expressed excitement about the milestone in developing a novel MRI contrast agent that can evaluate and detect leaky bladder.

“As a urologist, I know my clinical colleagues would highly welcome a new objective diagnostic modality that can accurately measure impaired bladder permeability and function,” said Dr. Chancellor.

Professor Pradeep Tyagi, a renowned scholar in the field of bladder pharmacology and imaging, emphasized that the agent can objectively phenotype IC/BPS that is bladder-centric, thereby identifying patients who would be most likely to benefit from clinical trials of newer therapies targeting bladder pathology and avoid the delay in getting appropriate medical care.

  1. Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development Read more
  2. Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer Read more
  3. Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia Read more
  4. Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis Read more
  5. Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency Read more